



Construction continues on schedule

IDT Biologika celebrates the topping off of its new research building in Riems

*Riems, March 4, 2016* – **IDT Biologika (Riems) has reached the milestone of completing the building shell as planned. Interior construction, fittings, and administrative approvals are the next steps in construction of the new laboratory building. IDT Biologika celebrated the topping out placement of the last beam with guests including Economics Minister Harry Glawe.**

Research and quality control will have their future home in a modern building with state-of-the-art facilities at IDT Biologika in Riems. The topping out ceremony celebrates an important step towards occupation of the new building in Riems. “We completed the building shell as planned at the start of 2016, and are now starting on the interior construction of the research building,” declared Dr. Ralf Pfirmann, Chief Executive Officer of IDT Biologika. “When the new building is approved and begins operation, IDT in Riems will make an important contribution to the development and manufacture of IDT Biologika vaccines. We have advanced IDT’s reputation well beyond German borders in the past year, with important vaccine projects, a new location in the US and expanded collaboration with the Bill & Melinda Gates Foundation – our expertise is now recognized worldwide. We continue to pursue globalization for our Animal Health business. Riems will play a key role in developing innovative animal health vaccines.”

“This investment is an investment in the future. At the Riems production site for veterinary vaccines and medicines, quality jobs in the pharmaceutical industry are being created and secured. These are



exactly the types of science-based jobs that our state urgently needs, and that our technology and economics policy seeks to support," said Harry Glawe, Mecklenburg-Western Pomeranian Minister for Economics, Construction and Tourism at the ceremony.

After the Riems site was acquired by IDT Biologika in autumn 2013, IDT Biologika (Riems) became an integral part of IDT Biologika. It is already developing and manufacturing innovative products to fight disease in animals, which are marketed worldwide.

The necessary expansion of the IDT site in Riems for research and quality control is being achieved with an investment of some €12 million. The German state of Mecklenburg-Western Pomerania is supporting the project with a 25% grant.

"The new research and quality control building will hold a total of 27 laboratories for both functions. The workstations will be state-of-the-art and use cutting-edge technologies," said Dr. Jörg Köhler, Managing Director of IDT Biologika (Riems). "The topping off is a key step on the way to certification, and we are pleased to celebrate it with our employees and guests today. Construction is on schedule, and after the interior is constructed and the necessary machines and systems are installed, approval of the project's laboratories will complete the process. We hope to celebrate the building's dedication, and above all its start of operation, in 2017."

The 27 new laboratories in Riems will include two that are equipped for BSL-3 (biosafety level 3) research. The laboratories, including specialized labs for industrial development and quality control, will meet GMP (Good Manufacturing Practice) requirements for medication production. The new laboratory building totaling 1,800 square meters should be completed by the end of 2016, with certification of the laboratories expected by mid-2017. Modernization of the site's



manufacturing and logistics infrastructure also began in 2015 with an investment of some €2 million.

### **About IDT Biologika in Riems**

*IDT Biologika (Riems) GmbH & Co KG is a subsidiary of IDT Biologika GmbH with headquarters in Riems-Greifswald. The company currently has 60 employees researching and producing vaccines for veterinary medicine applications.*

### **About IDT Biologika**

*IDT Biologika is an innovative, privately-held company with more than 90 years of experience in researching, developing, manufacturing and marketing products for human and animal health. Established in 1921, IDT Biologika has become one of the world's leading pharmaceutical and biotechnological companies, producing vaccines and pharmaceuticals according to the highest quality national and international market standards. Company sites in Germany include the BioPharmaPark in Dessau-Rosslau and the Riems district of Greifswald. The IDT offices in Denmark, the Netherlands, France, Spain and Canada are focused on the Animal Health business segment. In June, 2015, IDT Corporation established a production site for clinical test samples -in Rockville, Maryland, USA.*

*In 2015 IDT Biologika registered sales of €202 million in the animal health, vaccines, parenteral products, biologics and drug packaging business segments, a 17 percent increase over the previous year. IDT Biologika currently employs around 1,500 workers.*

*IDT Biologika is a Klocke Holding company. Klocke Holding is a family-run company with 2,100 employees and eight production sites. Klocke Holding companies are specialized in contract production and packaging of medications, vaccines and cosmetic products.*

### **Contact:**

**Peter Kellner**

Phone +49 34901 885 5681



Mobile +49 162 4248453

Peter.Kellner@idt-biologika.de

**IDT Biologika GmbH**

Am Pharmapark, 06861 Dessau-Rosslau, Germany